首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1377407

口乾症治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，2018-2028 按類型、產品、地區、競爭預測和機會細分，2018-2028F

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Product, By Region, By Competition Forecast & Opportunities, 2018-2028F

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022 年，全球口乾症治療市場價值為 19.8 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為3.69%。由於化療和治療的日益普及，預計該市場成長將顯著推動。用於癌症治療的放射療法，以及處方藥物的使用不斷增加。口乾症的特徵是唾液分泌減少導致口腔乾燥，可導致口乾、口腔灼熱感、吞嚥困難以及味覺減退或喪失。化學治療和放射治療會損害唾液腺，導致口乾。化療是腫瘤學家和醫生提供的最常見的癌症治療方法，通常會導致口乾症的副作用。此外，口乾症也可能由藥物、頭頸部放射治療、化療甚至乾燥症引起。截至 2016 年 1 月 1 日，美國癌症協會報告稱，美國有 350 萬名女性患有乳癌。在患有 IV 期乳癌的女性中，48% 接受放射治療和/或化學治療作為治療的一部分。

主要市場促進因素

導致口乾症的發生率不斷增加

市場概況
預測期	2024-2028
2022 年市場規模	19.8億美元
2028 年市場規模	24.4億美元
2023-2028 年CAGR	3.69%
成長最快的細分市場	場外交易
最大的市場	北美洲

口乾症通常稱為口乾，是一種以唾液流量減少為特徵的常見病症。雖然口乾症看起來似乎是一個小小的不便，但它會對個人的生活品質產生重大影響，影響他們說話、吃飯甚至享受食物的能力。全球口乾症治療市場正在經歷顯著成長，而這種擴張背後的關鍵促進因素之一是導致口乾症的發病率不斷增加。癌症是導致口乾症發生率增加的主要原因。化學治療和放射治療是兩種常見的癌症治療方法，通常會導致唾液腺受損，導致口乾。隨著全球癌症負擔持續上升，因這些治療的副作用而出現口乾症的患者數量也在增加。這創造了大量尋求緩解口乾的患者群體，從而推動了對口乾症治療的需求。世界人口正在老化，老年人口的比例比以往任何時候都高。隨著年齡的成長，他們往往會出現多種需要藥物治療的健康問題。許多這些藥物都有口乾的副作用。隨著老年人服用更多藥物，該族群口乾的盛行率正在上升。這種人口結構的變化極大地促進了口乾症治療市場的成長。多重用藥，即一個人同時使用多種藥物，正變得越來越普遍。患有慢性疾病的人經常服用多種藥物來控制疾病，這可能會增加口乾症副作用的可能性。這種現象增加了對口乾症治療的需求，因為越來越多的患者需要有效的解決方案來緩解口乾症狀。乾燥症（一種主要影響唾液腺和淚腺的自體免疫疾病）等疾病可能會導致慢性口乾。自體免疫疾病的盛行率正在上升，這對患有口乾症的人數有直接影響。隨著人們對這些疾病的認知不斷增強，越來越多的患者被診斷出來，對口乾症治療的需求不斷增加。醫療保健專業人員越來越擅長診斷口乾症並認知到它是一個重要的健康問題。這種改進的診斷和報告導致更多的患者尋求針對口乾症狀的治療，進一步推動了口乾症治療市場的發展。

市場規模及預測
- 按價值
市佔率及預測
- 依類型（非處方藥、處方藥）
- 依產品（唾液興奮劑、唾液替代品、潔齒劑）
- 按國家/地區
MEA：國家分析
- 南非口乾症治療公司
- 沙烏地阿拉伯口乾症治療
- 阿拉伯聯合大公國口乾症治療公司
- 科威特口乾症治療

第 11 章：市場動態

促進要素
挑戰

第 12 章：市場趨勢與發展

近期發展
併購
產品發布

第 13 章：波特的五力分析

產業競爭
新進入者的潛力
供應商的力量
客戶的力量
替代產品的威脅

第14章：競爭格局

商業概覽
產品供應
最近的發展
財務（據報導）
主要人員
SWOT分析
- Acacia Pharma Ltd
- Parnell Pharmaceuticals Holdings Ltd
- Pfizer Inc
- GSK PLC
- Church & Dwight Co Inc
- Lupin Pharmaceuticals Inc
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC.
- Pendopharm Inc
- OraCoat

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄

Product Code: 16619

Global Xerostomia Therapeutics Market has valued at USD 1.98 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 3.69% through 2028. The market growth is expected to receive a significant boost due to the increasing adoption of chemotherapy and radiotherapy for cancer treatment, along with the rising use of prescribed medications. Xerostomia, characterized by oral dryness resulting from reduced saliva production, can lead to sensations of mouth dryness, oral burning, difficulty in swallowing, and a decrease or loss of taste. The salivary glands are damaged by chemotherapy and radiation therapy, resulting in dry mouth. Chemotherapy, the most common cancer treatment provided by oncologists and medical practitioners, often leads to xerostomia as a side effect. Additionally, xerostomia can be caused by medication, head and neck radiation therapy, chemotherapy, and even Sjogren's syndrome. As of January 1, 2016, the American Cancer Society reported that 3.5 million women in the U.S. were living with breast cancer. Among women with stage IV breast cancer, 48% received radiation and/or chemotherapy as part of their treatment.

Key Market Drivers

Increasing Incidence of Xerostomia-Causing Conditions

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 1.98 Billion
Market Size 2028	USD 2.44 Billion
CAGR 2023-2028	3.69%
Fastest Growing Segment	OTC
Largest Market	North America

Xerostomia, commonly known as dry mouth, is a prevalent condition characterized by a reduced flow of saliva. While it may seem like a minor inconvenience, xerostomia can have a significant impact on an individual's quality of life, affecting their ability to speak, eat, and even enjoy food. The global xerostomia therapeutics market is experiencing remarkable growth, and one of the key drivers behind this expansion is the increasing incidence of xerostomia-causing conditions. Cancer is a major contributor to the increasing incidence of xerostomia-causing conditions. Chemotherapy and radiation therapy, two common treatments for cancer, often lead to damage to the salivary glands, resulting in dry mouth. As the global cancer burden continues to rise, the number of patients experiencing xerostomia as a side effect of these treatments is also increasing. This creates a substantial patient pool seeking relief from dry mouth, thus driving the demand for xerostomia therapeutics. The world's population is aging, with a higher proportion of elderly individuals than ever before. As people age, they tend to develop multiple health issues that require medication. Many of these medications have xerostomia as a side effect. With the elderly population taking more medications, the prevalence of dry mouth among this demographic is on the rise. This demographic shift significantly contributes to the growth of the xerostomia therapeutics market. Polypharmacy, the concurrent use of multiple medications by an individual, is becoming increasingly common. People with chronic health conditions often take multiple drugs to manage their ailments, which can increase the likelihood of experiencing xerostomia as a side effect. This phenomenon amplifies the demand for xerostomia therapeutics as more patients require effective solutions to alleviate dry mouth symptoms. Conditions like Sjogren's syndrome, an autoimmune disease that primarily affects the salivary and tear glands, can lead to chronic dry mouth. The prevalence of autoimmune diseases is on the rise, and this has a direct impact on the number of individuals experiencing xerostomia. As awareness of these diseases grows and more patients are diagnosed, the demand for xerostomia therapeutics continues to increase. Healthcare professionals are becoming more adept at diagnosing xerostomia and recognizing it as a significant health concern. This improved diagnosis and reporting have led to more patients seeking treatment for their dry mouth symptoms, further bolstering the xerostomia therapeutics market.

Advances in Xerostomia Therapeutics

Xerostomia, commonly referred to as dry mouth, is a condition characterized by insufficient saliva production, leading to discomfort and potential oral health complications. It affects millions of individuals worldwide and can be caused by various factors, including medication, radiation therapy, and systemic diseases. The global xerostomia therapeutics market is witnessing significant growth, primarily due to continuous advancements in treatment options. One of the most prominent factors contributing to the growth of the xerostomia therapeutics market is the development of innovative medications specifically designed to combat dry mouth. Pharmaceutical companies are investing in research and development to create drugs that stimulate salivary gland function or mimic the properties of saliva. These breakthrough medications offer patients more effective and targeted relief from xerostomia symptoms. Advances in the formulation of saliva substitutes have provided patients with viable alternatives to natural saliva. These substitutes aim to replicate the properties of saliva, such as lubrication and pH balance, to alleviate dry mouth symptoms effectively. As these products become more sophisticated and accessible, they contribute significantly to the growth of the xerostomia therapeutics market. Biotechnology plays a crucial role in the development of xerostomia therapeutics. Researchers are exploring biotechnological approaches to stimulate saliva production and improve the overall oral health of individuals suffering from dry mouths. These innovations offer promising solutions and enhance the market's potential for growth. Advances in healthcare technology enable the customization of xerostomia treatment plans for individual patients. With the availability of personalized therapies, healthcare providers can tailor interventions to the unique needs and preferences of each patient. This tailored approach not only enhances patient satisfaction but also drives demand for xerostomia therapeutics. Drug delivery systems have evolved significantly, making it easier for patients to administer xerostomia therapeutics. Improved formulations, such as oral sprays, gels, and lozenges, offer convenience and more effective delivery of medications or substitutes, further boosting patient compliance and market growth. Advances in patient education and awareness campaigns have led to increased recognition of the importance of managing xerostomia. As more individuals become aware of the available treatment options, they are likely to seek out therapies that provide relief from dry mouth symptoms, driving market expansion.

Growing Awareness and Diagnosis Rates

Xerostomia, more commonly known as dry mouth, is a condition characterized by a reduced production of saliva, which can result in significant discomfort and oral health issues. It is caused by various factors, including medication, radiation therapy, and certain medical conditions. The global xerostomia therapeutics market is on a growth trajectory, largely driven by the increasing awareness of this condition among both patients and healthcare professionals, as well as the improved rates of diagnosis. One of the key factors driving the growth of the xerostomia therapeutics market is the increasing emphasis on patient education. Healthcare organizations, advocacy groups, and pharmaceutical companies are actively engaged in educational campaigns to raise awareness about xerostomia. Patients are now better informed about the condition's symptoms and consequences, which leads to a higher likelihood of seeking medical assistance and treatment. Healthcare professionals, including dentists, oncologists, and primary care physicians, are becoming more proficient in recognizing xerostomia. They are now better equipped to identify the condition's signs during routine examinations and consultations. As a result, patients are being diagnosed more accurately and promptly, leading to an increased demand for xerostomia therapeutics. Xerostomia is often a symptom of underlying health conditions, such as Sjogren's syndrome or diabetes. As awareness of these conditions grows, so does the recognition of xerostomia as a related concern. Patients with these underlying conditions are more likely to be screened for dry mouth, thus contributing to increased diagnosis rates and the demand for appropriate therapeutics. The internet and various media outlets have played a significant role in disseminating information about xerostomia. Patients can easily access information about the condition's causes, symptoms, and available treatments. This ease of access empowers individuals to seek help and inquire about xerostomia therapeutics during medical appointments. The development of improved diagnostic tools and techniques has facilitated the identification of xerostomia. Salivary flow tests, imaging, and other diagnostic methods have become more precise, allowing healthcare providers to diagnose dry mouth more accurately. This, in turn, drives the demand for xerostomia therapeutics.

Research and Development Efforts

Xerostomia, commonly known as dry mouth, is a medical condition characterized by a lack of saliva production in the mouth. This condition can be caused by various factors, including medication side effects, medical treatments, and underlying health conditions. Xerostomia not only affects the comfort and quality of life for those who suffer from it but also poses potential risks to oral health. As the global population ages and the prevalence of xerostomia continues to rise, there is a pressing need for effective therapeutic solutions. Research and development (R&D) efforts play a pivotal role in addressing this need and driving the growth of the global xerostomia therapeutics market. Xerostomia is not merely an inconvenience but a condition that can have far-reaching consequences. Saliva plays a crucial role in maintaining oral health by helping to digest food, neutralizing acids, and preventing tooth decay. The xerostomia therapeutics market is poised for significant growth, primarily due to the aging population and the rising prevalence of conditions such as Sjogren's syndrome, diabetes, and cancer, which are known to cause dry mouth. R&D endeavors can lead to the development of innovative therapies tailored to address the specific causes and symptoms of xerostomia. These may include pharmaceuticals, biologics, and advanced oral care products. Research can help identify biomarkers and genetic factors that contribute to xerostomia. This knowledge can pave the way for personalized treatment approaches, ensuring better outcomes for patients. R&D allows for rigorous clinical trials and studies that evaluate the safety and efficacy of xerostomia therapies. This data is vital for gaining regulatory approvals and building trust among healthcare providers and patients. R&D efforts can also contribute to increased awareness and education about xerostomia among both healthcare professionals and the general public, leading to earlier diagnosis and treatment. As new and improved xerostomia therapies emerge, the global market for these treatments is expected to expand significantly. This growth not only benefits pharmaceutical companies but also creates opportunities for healthcare professionals and patients alike. To harness the full potential of R&D in boosting the xerostomia therapeutics market, collaboration between pharmaceutical companies, research institutions, healthcare providers, and patient advocacy groups is essential. This synergy can expedite the development of promising therapies and ensure they reach the market sooner. Investment in R&D is equally crucial. Governments, private investors, and philanthropic organizations can play a pivotal role in funding research initiatives focused on xerostomia. These investments can help accelerate breakthroughs and reduce the time it takes for new treatments to become available to those in need.

Key Market Challenges

Limited Understanding of Xerostomia Causes

One of the primary challenges in the xerostomia therapeutics market is the limited understanding of the diverse causes of dry mouth. While some cases are medication-induced, others result from medical treatments or underlying health conditions. Identifying the exact cause of xerostomia in each patient is essential for tailoring effective treatments. The lack of comprehensive knowledge can lead to misdiagnoses and ineffective therapies.

Complexity of Treatment Approaches

Xerostomia is a multifaceted condition with numerous contributing factors. Developing effective treatments that address these complexities is challenging. Traditional approaches often focus on symptomatic relief, such as saliva substitutes or stimulants. However, addressing the root causes of xerostomia, such as salivary gland dysfunction or autoimmune diseases like Sjogren's syndrome, requires innovative and personalized therapies. These approaches can be expensive and time-consuming to develop.

Patient Compliance and Adherence

Even when effective treatments are available, patient compliance and adherence can be problematic. Xerostomia may be a chronic condition, and patients may need to use therapies consistently for prolonged periods. Overcoming the inconvenience and potential side effects of treatments can be a barrier to patient adherence, reducing treatment efficacy.

Cost of Therapies

Some xerostomia therapeutics, particularly novel and innovative treatments, can be costly. This cost can be a significant burden for patients, particularly when treatments are not covered by insurance or healthcare systems. Access to affordable therapies is crucial for ensuring that xerostomia patients receive the care they need.

Key Market Trends

Personalized Medicine and Biomarker Development

One of the most promising trends in the xerostomia therapeutics market is the move towards personalized medicine. Researchers are actively identifying biomarkers and genetic factors that contribute to xerostomia. This allows for tailoring treatments to individual patients, increasing treatment efficacy, and minimizing side effects. By understanding the unique genetic and physiological aspects of each patient, healthcare providers can prescribe treatments that are more likely to succeed.

Innovative Drug Formulations

Innovations in drug formulation are paving the way for more convenient and effective xerostomia treatments. Recent developments include novel drug delivery systems such as mouth sprays, gels, and mucoadhesive patches. These formulations aim to provide longer-lasting relief, enhance patient compliance, and improve the overall treatment experience.

Digital Health Solutions

The integration of digital health solutions is transforming the way xerostomia is managed. Mobile apps, wearable devices, and telehealth platforms are being developed to help patients monitor their oral health, track medication adherence, and receive real-time guidance from healthcare professionals. These digital tools not only empower patients but also enable remote monitoring and data-driven treatment adjustments.

Natural and Herbal Remedies

Consumer interest in natural and herbal remedies is influencing the xerostomia therapeutics market. Several herbal products and natural supplements are gaining popularity for their potential to alleviate dry mouth symptoms. Research is ongoing to validate the safety and efficacy of these remedies, which could provide alternative options for patients seeking holistic approaches to managing xerostomia.

Segmental Insights

Type Insights

Based on the category of Type, the market can be divided into two segments: Over-the-Counter (OTC) and prescription. In 2022, the OTC segment held the largest market share, and it is anticipated to exhibit significant growth at a favorable compound annual growth rate (CAGR) throughout the projected period. This dominance can be attributed to several factors, including the wide range of available products, their safety and effectiveness, the presence of limited branded drugs, and competitive pricing.

OTC products represent the primary approach for addressing xerostomia, and for most cases of xerostomia, these products are sufficient and pose no complications. In instances of severe xerostomia, prescription medications may be necessary. Through proper care and medication, xerostomia can be effectively managed and controlled, thereby preventing any potential complications.

Product Insights

The market can be segmented based on product into salivary stimulants, salivary substitutes, and dentifrices. In 2022, the salivary stimulants segment was the market leader. Salivary stimulants are substances designed to enhance the production of saliva and can be further categorized as pharmacological (affecting the nervous system) or non-pharmacological (influencing taste buds or chewing muscles). They come in various forms, including mints, sugar-free chewing gums, sprays, and lozenges. In November 2018, 3M introduced the Xerostomia Relief Spray, which provides relief for up to 4 hours by moistening and lubricating mucosa. In September 2021, ICPA Health Products Ltd. launched Wet Mouth, a saliva substitute based on sodium carboxymethyl cellulose, designed to treat xerostomia and reduce surface abrasion.

The dentifrices segment is projected to experience the most rapid growth in terms of CAGR during the forecast period. Dentifrices are specialized dental cleaning agents, powders, or pastes that help alleviate dry mouth by eliminating irritants that contribute to dryness. GC America Inc.'s MI Paste and MI Paste Plus are products that can be applied to the teeth to stimulate saliva production and restore essential saliva components such as calcium and phosphate.

Regional Insights

In 2022, the North American region emerged as the dominant player in the market. The primary factors contributing to this dominance include the growing prevalence of conditions like xerostomia and related ailments such as Sjogren's syndrome and rheumatoid arthritis. Additionally, the increasing awareness campaigns focused on dry mouth have played a pivotal role in this dominance. Notably, the Sjogren's Foundation's "April is Sjogren's Awareness Month" campaign has significantly contributed to raising awareness about Sjogren's syndrome.

Looking ahead, the Asia Pacific region is expected to exhibit the most rapid CAGR during the forecast period. This growth can be attributed to several key factors, including the escalation in healthcare expenditure, heightened awareness campaigns, and a rising incidence of conditions like diabetes, cancer, and Parkinson's disease. According to a study conducted by the National Institutes of Health (NIH), between 1990 and 2019, the occurrences of Parkinson's disease witnessed substantial increases in East Asia, South Asia, Southeast Asia, and Central Asia, with growth rates of 202.22%, 204.06%, 164.21%, and 67.93%, respectively.

Key Market Players

Acacia Pharma Ltd

Parnell Pharmaceuticals Holdings Ltd

Pfizer Inc

GSK PLC

Church & Dwight Co Inc

Lupin Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd

Hikma Pharmaceuticals PLC.

Pendopharm Inc

OraCoat

Report Scope:

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type:

OTC
Prescription

Xerostomia Therapeutics Market, By Product:

Salivary Stimulants
Salivary Substitutes
Dentifrices

Xerostomia Therapeutics Market, By Region:

North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

Global Xerostomia Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xerostomia Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (OTC, Prescription)
- 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Product Market Map
- 5.3.1. By Type
- 5.3.2. By Product
- 5.3.3. By Region

6. North America Xerostomia Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type (OTC, Prescription)
- 6.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Xerostomia Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Product
- 6.3.2. Canada Xerostomia Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Product
- 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type (OTC, Prescription)
- 7.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Xerostomia Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Product
- 7.3.2. United Kingdom Xerostomia Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Product
- 7.3.3. France Xerostomia Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Product
- 7.3.4. Italy Xerostomia Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Product
- 7.3.5. Spain Xerostomia Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Product

8. Asia-Pacific Xerostomia Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type (OTC, Prescription)
- 8.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Xerostomia Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Product
- 8.3.2. Japan Xerostomia Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Product
- 8.3.3. India Xerostomia Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Product
- 8.3.4. Australia Xerostomia Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Product
- 8.3.5. South Korea Xerostomia Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Product

9. South America Xerostomia Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type (OTC, Prescription)
- 9.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Xerostomia Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Product
- 9.3.2. Argentina Xerostomia Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Product
- 9.3.3. Colombia Xerostomia Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Product

10. Middle East and Africa Xerostomia Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type (OTC, Prescription)
- 10.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Xerostomia Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Product
- 10.3.2. Saudi Arabia Xerostomia Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Product
- 10.3.3. UAE Xerostomia Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Product
- 10.3.4. Kuwait Xerostomia Therapeutics Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Type
    - 10.3.4.2.2. By Product

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
- 14.6.1. Acacia Pharma Ltd
- 14.6.2. Parnell Pharmaceuticals Holdings Ltd
- 14.6.3. Pfizer Inc
- 14.6.4. GSK PLC
- 14.6.5. Church & Dwight Co Inc
- 14.6.6. Lupin Pharmaceuticals Inc
- 14.6.7. Sun Pharmaceutical Industries Ltd
- 14.6.8. Hikma Pharmaceuticals PLC.
- 14.6.9. Pendopharm Inc
- 14.6.10. OraCoat